Cellectis (NASDAQ:CLLS) Given New $10.00 Price Target at Oppenheimer

Cellectis (NASDAQ:CLLS) had its target price decreased by Oppenheimer from $11.00 to $10.00 in a research report report published on Wednesday, Benzinga reports. Oppenheimer currently has an outperform rating on the biotechnology company’s stock.

Other equities research analysts have also issued research reports about the stock. StockNews.com started coverage on shares of Cellectis in a research note on Thursday, June 6th. They issued a sell rating on the stock. JMP Securities restated a market outperform rating and issued a $6.00 price target on shares of Cellectis in a research note on Friday, May 31st.

Cellectis Stock Performance

Shares of NASDAQ CLLS opened at $2.25 on Wednesday. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.69. The firm’s 50-day moving average price is $2.74 and its two-hundred day moving average price is $2.82. Cellectis has a 52-week low of $0.96 and a 52-week high of $3.77. The stock has a market capitalization of $125.06 million, a P/E ratio of -1.74 and a beta of 3.09.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Monday, April 29th. The biotechnology company reported ($0.64) EPS for the quarter. Cellectis had a negative net margin of 529.81% and a negative return on equity of 67.41%. The firm had revenue of $1.99 million during the quarter. As a group, sell-side analysts forecast that Cellectis will post -0.96 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cellectis stock. Baillie Gifford & Co. lifted its stake in shares of Cellectis S.A. (NASDAQ:CLLS) by 1.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 827,248 shares of the biotechnology company’s stock after acquiring an additional 10,605 shares during the quarter. Baillie Gifford & Co. owned about 1.49% of Cellectis worth $2,192,000 at the end of the most recent reporting period. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.